Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
MENLO PARK, Calif., March 02, 2016 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a gene therapy company committed to discovering and developing novel medicines for patients with chronic or debilitating disease, today announced that Paul B. Cleveland, president and chief executive officer of Avalanche, will present at two upcoming investor conferences:
- Cowen and Company’s 36th Annual Health Care Conference on Wednesday, March 9 at 9:20 a.m. ET in Boston, and
- Alliance for Regenerative Medicine’s 4th Annual Cell and Gene Therapy Investor Day on Tuesday, March 22 at 4:50 p.m. ET in New York.
A recorded webcast of Mr. Cleveland’s presentation at the Cowen and Company conference will be made available for replay under the Investors section of Avalanche’s website at www.avalanchebiotech.com.
About Avalanche Biotechnologies, Inc.
Avalanche is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients suffering from chronic or debilitating disease. Avalanche is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. With significant capabilities and expertise in vector optimization, process development and manufacturing, Avalanche seeks to discover and develop targets in ophthalmology and beyond.
Contacts Lauren Glaser, Head of Investor Relations (650) 656-9347 [email protected]
